Description: Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
Home Page: www.biotron.com.au
BIT Technical Analysis
Marshall Funds Inc
,
Phone:
800-236-3863
Officers
| Name | Title |
|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Exec. Director |
| Mr. Peter James Nightingale B.Econ, CA | Company Sec. |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 22.2904 |
| Price-to-Sales TTM: | 15.6252 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |